Biohaven Ltd

Bailey Gregory’s 68,693‑option purchase at Biohaven signals executive confidence—watch the upcoming clinical milestones and vesting dates for potential upside.

Insider buying spree at Biohaven shows top execs betting on a price rebound tied to clinical milestones—discover how this bullish move could boost investors.

Biohaven CFO’s 175k‑option buy signals strong insider confidence and potential upside as the company targets FDA approvals, despite a 70% stock decline.

Insider buying at Biohaven signals cautious confidence amid a 68 % price drop, hinting at long‑term value and potential upside.